Management of macular edema with branch retinal vein occlusion in a case of secondary polycythemia

oc000127 10.3205/oc000127 urn:nbn:de:0183-oc0001272 Case Report Management of macular edema with branch retinal vein occlusion in a case of secondary polycythemia Singh Singh Sumeer S

Elite School of Optometry, Chennai, India

author Neriyanuri Neriyanuri Srividya S

Elite School of Optometry, Chennai, India

author Raman Raman Rajiv R Dr.

Shri Bhagawan Mahavir Vitreoretinal Services, Sankara Nethralaya, 18 College Road, Chennai – 600 006, Tamil Nadu, India, Phone:+91-44-28271616, Fax: +91-44-28254180Shri Bhagawan Mahavir Vitreoretinal Services, Sankara Nethralaya Hospital, Chennai, India

rajivpgraman@gmail.com author German Medical Science GMS Publishing House

Düsseldorf

610 polycythemia macular edema branch retinal vein occlusion intravitreal injections 20191120 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). 2193-1496 9 GMS Ophthalmology Cases GMS Ophthalmol Cases 38 Purpose: We report a case of polycythemia with an ocular complication of branch retinal vein occlusion associated with macular edema that was managed by anti-vascular endothelial growth factor (VEGF) and systemic management.Methods: A 43-year-old, one-eyed male, a known case of polycythemia presented with complaints of decreased vision in the right eye. He underwent comprehensive eye evaluation, fundus photography and optical coherence tomography at the baseline visit and post intravitreal ranibizumab 1-, 3-, 4- and 11-month follow-up. Results: A patient with polycythaemia was diagnosed in the right eye with superotemporal branch retinal vein occlusion and macular edema, which clinically and on optical coherence tomography resolved after 1 intravitreal</PlainText></TextGroup> injection of ranibizumab. However, as he discontinued systemic management, macular edema reappeared and the edema resolved well after intravitreal ranibizumab. He then became more compliant to the systemic therapy and was asymptomatic for the last <TextGroup><PlainText>7 months</PlainText></TextGroup>. </Pgraph><Pgraph><Mark1>Conclusion:</Mark1> In a case of retinal vein occlusion with macular edema of recognizable cause, the management of systemic disease and <TextGroup><PlainText>anti-VEGF</PlainText></TextGroup> can give satisfactory results.</Pgraph></Abstract> <TextBlock linked="yes" name="Introduction"> <MainHeadline>Introduction</MainHeadline><Pgraph>Polycythemia vera or primary polycythemia is a myeloproliferative disorder characterized by the presence of increased red blood cells, haemoglobin and total blood volume and occurs due to a JAK2 mutation <TextLink reference="1"></TextLink>. Haematological alterations in primary polycythemia give rise to prothrombosis, an event that results in serious ocular and systemic manifestations <TextLink reference="2"></TextLink>, <TextLink reference="3"></TextLink>. Secondary polycythemia is a heterogeneous group of disorders which results in abnormal increase in blood cell mass due to a decrease in tissue oxygenation and alterations in production of erythropoietin. Previous reports have shown a presence of bilateral retinal vein occlusion as initial manifestation of polycythemia <TextLink reference="4"></TextLink>. There has been paucity of information on ocular complications in patients with secondary polycythemia. </Pgraph><Pgraph>We report a case of secondary polycythemia who presented to us with unilateral branched retinal vein occlusion with macular edema and was managed by phlebotomy and intravitreal ranibizumab. The case highlights the importance of treatment of the systemic disease in reducing the need of intravitreal injections and implications in recurrence of macular edema. To the best of our knowledge, macular edema with branch retinal vein occlusion (BRVO) as a complication of secondary polycythemia was not reported earlier.</Pgraph></TextBlock> <TextBlock linked="yes" name="Case description"> <MainHeadline>Case description</MainHeadline><Pgraph>A 43-year-old male presented to a tertiary eye care centre with complaints of sudden onset (3 days) blurring of vision in the right eye. He was one-eyed and had lost his left eye 20 years ago following a traumatic injury. He was a heavy smoker and gave a positive history of alcohol consumption. He was a known case of polycythemia since <TextGroup><PlainText>6 months</PlainText></TextGroup>; he was negative for JAK2 mutation and had high haematocrit values (Table 1 <ImgLink imgNo="1" imgType="table"/>) indicating a secondary polycythemia according to the guidelines set by the British Committee for Standards in Haematology <TextLink reference="5"></TextLink>. He was on systemic anti-hypertensive treatment and was advised phlebotomy. However, he was non-compliant to phlebotomy.</Pgraph><Pgraph>On clinical examination, his best corrected visual acuity (BCVA) was 6/7.5 for distance and N6 for near in the right eye. Anterior segment evaluation was normal and intraocular pressure by applanation tonometry was <TextGroup><PlainText>14 mm</PlainText></TextGroup> Hg in the right eye. Dilated fundus evaluation revealed a superotemporal branch retinal vein occlusion (ST BRVO) with macular edema. Cirrus high definition optical coherence tomography (Carl Zeiss Meditec, Germany) using macular cube (A scans 512, B scans 128) and 5-line raster scans (4096 A-scans) showed an increased central subfield foveal thickness (358 microns) with the presence of cystoid macular edema (CME) and subretinal fluid (SRF). As the patient was symptomatic, even though his vision was good, he was advised intravitreal anti-VEGF and a review with his physician for phlebotomy. The patient underwent intravitreal injection of ranibizumab (<TextGroup><PlainText>0.5 mg</PlainText></TextGroup>) and was advised to undergo phlebotomy regularly.</Pgraph><Pgraph>On th consecutive 1<Superscript>st</Superscript> and 2<Superscript>nd</Superscript> monthly follow-up visits, the patient was asymptomatic, his BCVA was 6/6 for distance and N6 for near. Optical coherence tomography (OCT) showed a normal central subfield foveal thickness (<TextGroup><PlainText>180 m</PlainText></TextGroup>icrons) with resolved CME and SRF (Figure 1 <ImgLink imgNo="1" imgType="figure"/>). </Pgraph><Pgraph>At the 3<Superscript>rd</Superscript> monthly visit, the patient complained of a sudden drop in vision. He was noncompliant to the treatment advised by his physician for secondary polycythemia. On ocular examination, there was a drop in BCVA to 6/18 with recurrence of CME (increased central subfield foveal thickness – 521 microns). He underwent intravitreal injection of ranibizumab (0.5 mg) at this visit. He was explained the need for compliance to systemic management. On the subsequent visit, the patient’s vision improved to 6/6, N6 and OCT showed resolving macular edema. </Pgraph><Pgraph>Thereafter, he was followed up monthly for 3 months and bimonthly for 1 year. On, the 1-year follow-up, the patient maintained a BCVA of 6/6, N6 with no recurrence of vein occlusion or macular edema (Figure 2 <ImgLink imgNo="2" imgType="figure"/>). He was under regular care of his treating physician for secondary polycythemia.</Pgraph></TextBlock> <TextBlock linked="yes" name="Discussion"> <MainHeadline>Discussion</MainHeadline><Pgraph>Ocular complications of polycythemia include retinal and choroidal ischemia, retinal haemorrhages, papilloedema and cilioretinal artery occlusion, all of which pose a risk of visual loss and transient blindness <TextLink reference="2"></TextLink>, <TextLink reference="6"></TextLink>. Phlebotomy, a bloodletting procedure for polycythemia, also reduces the risk of systemic and ocular morbidity <TextLink reference="6"></TextLink>, <TextLink reference="7"></TextLink>.</Pgraph><Pgraph>Systemic management together with an appropriate ocular management for macular edema and vascular occlusions plays a pivotal role in eye salvage. Previous studies demonstrate that intravitreal ranibizumab therapy is effective for the reduction of macular edema and improvement in visual acuity. PRN (pro re nata) dosing, treat and extend regimen are also effective in treating macular edema in BRVO rather than having monthly injections <TextLink reference="8"></TextLink> <TextLink reference="9"></TextLink>. In the present case, timely management of BRVO and strict adherence to the systemic management helped in the recovery of lost vision and halted the reoccurrence of macular edema. This case report brings out an important observation that in cases where the cause of BRVO is certain, treatment of the underlying cause is crucial as it helps to reduce the number of ocular injections a patient receives.</Pgraph><Pgraph>Thus, BRVO with macular edema secondary to hematological diseases like polycythemia can be managed by systemic control of the disease and as needed injection of intravitreal <TextGroup><PlainText>anti-VEGF</PlainText></TextGroup> agents. However, as there are issues of safety due to the hypercoagulable state of the blood, they need regular physician care and monitoring.</Pgraph></TextBlock> <TextBlock linked="yes" name="Notes"> <MainHeadline>Notes</MainHeadline><SubHeadline>Competing interests</SubHeadline><Pgraph>The authors declare that they have no competing interests.</Pgraph></TextBlock> <References linked="yes"> <Reference refNo="1"> <RefAuthor>Spivak JL</RefAuthor> <RefTitle>Polycythemia vera: myths, mechanisms, and management</RefTitle> <RefYear>2002</RefYear> <RefJournal>Blood</RefJournal> <RefPage>4272-90</RefPage> <RefTotal>Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002 Dec;100(13):4272-90. DOI: 10.1182/blood-2001-12-0349</RefTotal> <RefLink>http://dx.doi.org/10.1182/blood-2001-12-0349</RefLink> </Reference> <Reference refNo="2"> <RefAuthor>Parija S</RefAuthor> <RefAuthor>Mohapatra MM</RefAuthor> <RefAuthor>Pattnaik BK</RefAuthor> <RefTitle>Polycythemia vera presenting with bilateral papilledema: a rare case report</RefTitle> <RefYear>2008</RefYear> <RefJournal>Indian J Ophthalmol</RefJournal> <RefPage>327-9</RefPage> <RefTotal>Parija S, Mohapatra MM, Pattnaik BK. Polycythemia vera presenting with bilateral papilledema: a rare case report. Indian J Ophthalmol. 2008 Jul-Aug;56(4):327-9. DOI: 10.4103/0301-4738.41418</RefTotal> <RefLink>http://dx.doi.org/10.4103/0301-4738.41418</RefLink> </Reference> <Reference refNo="3"> <RefAuthor>Melamed E</RefAuthor> <RefAuthor>Rachmilewitz EA</RefAuthor> <RefAuthor>Reches A</RefAuthor> <RefAuthor>Lavy S</RefAuthor> <RefTitle>Aseptic cavernous sinus thrombosis after internal carotid arterial occlusion in polycythaemia vera</RefTitle> <RefYear>1976</RefYear> <RefJournal>J Neurol Neurosurg Psychiatry</RefJournal> <RefPage>320-4</RefPage> <RefTotal>Melamed E, Rachmilewitz EA, Reches A, Lavy S. Aseptic cavernous sinus thrombosis after internal carotid arterial occlusion in polycythaemia vera. J Neurol Neurosurg Psychiatry. 1976 Apr;39(4):320-4. DOI: 10.1136/jnnp.39.4.320</RefTotal> <RefLink>http://dx.doi.org/10.1136/jnnp.39.4.320</RefLink> </Reference> <Reference refNo="4"> <RefAuthor>Rodriguez N</RefAuthor> <RefAuthor>Eliott D</RefAuthor> <RefTitle>Bilateral central retinal vein occlusion in Eisenmenger syndrome</RefTitle> <RefYear>2001</RefYear> <RefJournal>Am J Ophthalmol</RefJournal> <RefPage>268-9</RefPage> <RefTotal>Rodriguez N, Eliott D. Bilateral central retinal vein occlusion in Eisenmenger syndrome. Am J Ophthalmol. 2001 Aug;132(2):268-9.</RefTotal> </Reference> <Reference refNo="5"> <RefAuthor>McMullin MF</RefAuthor> <RefTitle>The classification and diagnosis of erythrocytosis</RefTitle> <RefYear>2008</RefYear> <RefJournal>Int J Lab Hematol</RefJournal> <RefPage>447-59</RefPage> <RefTotal>McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 2008 Dec;30(6):447-59. DOI: 10.1111/j.1751-553X.2008.01102.x</RefTotal> <RefLink>http://dx.doi.org/10.1111/j.1751-553X.2008.01102.x</RefLink> </Reference> <Reference refNo="6"> <RefAuthor>Yang HS</RefAuthor> <RefAuthor>Joe SG</RefAuthor> <RefAuthor>Kim JG</RefAuthor> <RefAuthor>Park SH</RefAuthor> <RefAuthor>Ko HS</RefAuthor> <RefTitle>Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography</RefTitle> <RefYear>2013</RefYear> <RefJournal>Br J Haematol</RefJournal> <RefPage>745-7</RefPage> <RefTotal>Yang HS, Joe SG, Kim JG, Park SH, Ko HS. Delayed choroidal and retinal blood flow in polycythaemia vera patients with transient ocular blindness: a preliminary study with fluorescein angiography. Br J Haematol. 2013 Jun;161(5):745-7. DOI: 10.1111/bjh.12290</RefTotal> <RefLink>http://dx.doi.org/10.1111/bjh.12290</RefLink> </Reference> <Reference refNo="7"> <RefAuthor>Streiff MB</RefAuthor> <RefAuthor>Smith B</RefAuthor> <RefAuthor>Spivak JL</RefAuthor> <RefTitle>The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns</RefTitle> <RefYear>2002</RefYear> <RefJournal>Blood</RefJournal> <RefPage>1144-9</RefPage> <RefTotal>Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood. 2002 Feb;99(4):1144-9. DOI: 10.1182/blood.v99.4.1144</RefTotal> <RefLink>http://dx.doi.org/10.1182/blood.v99.4.1144</RefLink> </Reference> <Reference refNo="8"> <RefAuthor>Campochiaro PA</RefAuthor> <RefAuthor>Sophie R</RefAuthor> <RefAuthor>Pearlman J</RefAuthor> <RefAuthor>Brown DM</RefAuthor> <RefAuthor>Boyer DS</RefAuthor> <RefAuthor>Heier JS</RefAuthor> <RefAuthor>Marcus DM</RefAuthor> <RefAuthor>Feiner L</RefAuthor> <RefAuthor>Patel A</RefAuthor> <RefAuthor> RETAIN Study Group</RefAuthor> <RefTitle>Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study</RefTitle> <RefYear>2014</RefYear> <RefJournal>Ophthalmology</RefJournal> <RefPage>209-19</RefPage> <RefTotal>Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014 Jan;121(1):209-19. DOI: 10.1016/j.ophtha.2013.08.038</RefTotal> <RefLink>http://dx.doi.org/10.1016/j.ophtha.2013.08.038</RefLink> </Reference> <Reference refNo="9"> <RefAuthor>Brand CS</RefAuthor> <RefTitle>Management of retinal vascular diseases: a patient-centric approach</RefTitle> <RefYear>2012</RefYear> <RefJournal>Eye (Lond)</RefJournal> <RefPage>S1-16</RefPage> <RefTotal>Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond). 2012 Apr;26 Suppl 2:S1-16. DOI: 10.1038/eye.2012.32</RefTotal> <RefLink>http://dx.doi.org/10.1038/eye.2012.32</RefLink> </Reference> </References> <Media> <Tables> <Table format="png"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Table 1: Baseline laboratory evaluation for polycythemia</Mark1></Pgraph></Caption> </Table> <NoOfTables>1</NoOfTables> </Tables> <Figures> <Figure format="png" height="329" width="948"> <MediaNo>1</MediaNo> <MediaID>1</MediaID> <Caption><Pgraph><Mark1>Figure 1:</Mark1> <Mark1>Fundus pictures</Mark1><LineBreak></LineBreak>A: Fundus picture of the right eye showing a superotemporal branch retinal vein occlusion at the baseline visit. <LineBreak></LineBreak>B: Fundus picture at 1<Superscript>st</Superscript> follow-up, a month after anti-VEGF showing resolved superotemporal branch retinal vein occlusion.</Pgraph></Caption> </Figure> <Figure format="png" height="650" width="961"> <MediaNo>2</MediaNo> <MediaID>2</MediaID> <Caption><Pgraph><Mark1>Figure 2: Optical coherence tomography (OCT)</Mark1><LineBreak></LineBreak>A: OCT at the baseline visit shows an increased foveal contour with macular edema, photoreceptor layer and retinal pigment epithelium (RPE) layer are disrupted temporal to the fovea. <LineBreak></LineBreak>B: OCT at the 1<Superscript>st</Superscript> follow-up, a month after anti-VEGF shows resolved macular edema. <LineBreak></LineBreak>C: OCT at the 3<Superscript>rd</Superscript> monthly follow-up shows reoccurrence of the macular edema with sub retinal fluid noted. <LineBreak></LineBreak>D: OCT at the last visit, 11-month follow-up from the baseline shows completely resolved macular edema, normal inner and outer retinal layers noted.</Pgraph></Caption> </Figure> <NoOfPictures>2</NoOfPictures> </Figures> <InlineFigures> <NoOfPictures>0</NoOfPictures> </InlineFigures> <Attachments> <NoOfAttachments>0</NoOfAttachments> </Attachments> </Media> </OrigData> </GmsArticle>